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Summary 
Immune checkpoint blockade (ICB) is revolutionising cancer medicine, yet the molecular 
basis of resistance remains unclear. In this a recent issue of Cell, Benci et al demonstrate 
that sustained interferon signalling is central to the development of PD-L1-dependent and 
independent resistance to ICB.   
 
Preview  
Clinical experience with immune checkpoint blockade (ICB) has fuelled optimism but also 
engendered a critical question; why do these drugs fail in a fraction of patients? One 
explanation lies in the redundancy of T cell inhibitory receptor (TCIR) networks, evidenced 
by the superior efficacy of combination therapies (Larkin et al., 2015). Yet how tumours 
orchestrate and maintain adaptive resistance to ICB is unknown. This month, a study in Cell 
lead by Andy Minn demonstrates that upon prolonged interferon (IFN) exposure, melanoma 
cells adopt a state of Signal Transducer and Activator of Transcription 1 (STAT1)-dependent 
chronic resistance that is associated with epigenomic changes to the tumour, expression of 
interferon-stimulated genes (ISGs) and multiple TCIR ligands. 
 
To examine the basis of resistance to ICB, Benci et al. use concurrent radiotherapy (RT) and 
anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) to treat murine B16 melanoma, 
a strategy that yields 20% complete responses (CR), enabling the establishment of a 
resistant sub line from relapsed tumours (Res499). Genetic ablation of Programmed death-
ligand 1 (PD-L1) on Res499 cells fails to improve survival in the absence of ICB, but renders 
tumours partially sensitive to RT+CTLA-4 (CR 40%), an effect augmented in the presence of 
PD-L1 (CR 60%). The 40% late relapse in this latter experiment provides the authors with a 
cell line (JB2) that exhibits stable, PD-L1 independent resistance to ICB upon re-
transplantation. These two melanoma lines, together with parental B16 cells provides 
Minn’s group with a model to interrogate the mechanistic basis of PD-L1-dependent or -
independent resistance in vivo. Subsequently, Benci et al. show that prolonged in vitro 
exposure to IFN (but not type I IFN) promotes B16 melanoma resistance to ICB in vivo, 
whilst IFNGR KO Res499 cells recover sensitivity, in keeping with a key role for chronic IFN 
exposure in ICB resistance. Furthermore, the authors generate IFNAR KO and dual IFNAR 
and IFGR (IFNA/GR) double KO Res499 cells, demonstrating a role for both prolonged IFNG 
and IFNA signalling in ICB resistance. The contribution of IFN signalling in PD-L1-
independent resistance is also demonstrated by sensitising JB2 cells to ICB via ablation of 
IFNA/GR expression. In light of recent work demonstrating that mutations in IFN signalling 
pathways associate with resistance to ICB in humans (Zaretsky et al., 2016), Benci’s data 
appears paradoxical.  However, the authors highlight the importance of timing, showing 
that ablation of IFN signalling on B16 cells potentiates an effect exclusively upon delayed 
scheduling of dual CTLA-4 and PD-L1 treatment, consistent with a role for sustained and 
not early IFN signalling in resistance.  
 
To resolve the mechanisms underlying IFN signalling mediated resistance, B16 and Res499 
cells were transcriptionally and epigenetically profiled pre and post IFN treatment. This 
analysis provides 2 key findings: Acquisition of resistance in vivo and chronic IFN exposure 
in vitro generate an overlapping molecular footprint, and STAT1 is both elevated and its 
occupancy inferred at common open chromatin regions (OCRs). Critically, functional roles 
for STAT1 in producing this profile and mediating resistance are then underlined by loss of 
the key resistance signature and ICB resistance respectively, following STAT1 ablation. To 
enrich functionally relevant STAT1 targets, a panel of genes that are differentially expressed 
between B16 and Res499 was assessed, unveiling a correlation between STAT1, multiple 
TCIR ligands and ISGs (TNFRSF14, LGALS9, MHCII, IFIT, MX1) in ICB resistant melanoma cells, 
a molecular circuit the authors dub Interferon Driven ISGs and Inhibitory Ligands (IDILs). This 
signature is diminished when IFNA/GR are abolished on tumours in vivo, and intuitively, 
blocking the cognate TCIRs (TIM-3, LAG-3) of two of these gene products via monoclonal 
antibodies (mAbs) or by knocking out TNFRSF14 via CRISPR enhances survival during CTLA-
4+PD-L1 treatment of ICB resistant tumours (Res499 and Res237 breast cancer). Perhaps 
most intriguing is that the effect of IFN signalling seems to be only partly explained by this 
constellation of TCIR ligands, since survival in mice challenged with Res499 IFNA/GR KO 
tumours is superior to those treated with quadruple checkpoint blockade.  
 
To complement the examination of tumours, Benci et al subsequently measure T cell 
responses during ICB of mice challenged with Res499 and Res499 IFNA/GR KO or Res499 
STAT-1 KO tumours. ICB in Res499 IFNA/GR KO or Res499 STAT-1 KO challenged animals 
leads to an increased frequency of TRP2-reactive T cells bearing high levels of PD-1 and 
multiple TCIRs, and enhanced Ki67+GZMB+ cells amongst PD-1+ tumor-infiltrating 
lymphocytes (TILs) co-ordinately expressing TCIRs and Eomesodermin (Eomes), relative to 
Res499. The conclusion from these assays is that exhausted T cell populations, which 
accumulate during regulated anti-tumour responses, can be resurrected via targeting of IFN 
signalling in the tumour.  The rescue of such severely exhausted T cell populations has been 
proposed as a rate limiting step in the success of single agent ICB(Pauken and Wherry, 
2015). On this basis, the authors examine whether deletion of IFN signalling can rescue 
responses to CTLA-4 or PD-1 monotherapy. Encouragingly, delayed administration of JAK 
inhibitors or ablation of IFNA/GR receptor on the tumour facilitated marked and complete 
responses to monotherapy in resistant melanoma and breast tumours, respectively. 
 
Several lines of evidence are used to directly highlight the translational applicability of their 
pre-clinical findings. Amongst these, human homologues of the ISG and TCIR ligand genes 
expressed in Res499 were shown to significantly correlate with STAT1 expression in primary 
melanoma lysates, an association that is accentuated when PD-L1 levels are high. Also, low 
expression levels of 2 ISGs (IFIT1 and MX1) that form part of the chronic IFN resistance 
signature in mouse melanoma are shown to associate with improved clinical response to 
anti-PD-1.   
 
Although the pleotropic anti-tumour effects of IFN signalling are well described both in vitro 
and in vivo, the clinical efficacy of interferon as an anti-cancer therapy is limited. Evidence 
of prolonged recurrence-free survival in patients with melanoma treated in the adjuvant 
setting does not convincingly translate to an overall survival benefit in meta-analysis 
(Wheatley et al., 2003). Similarly, in advanced disease, IFN treatment in combination with 
chemotherapy has resulted in improved response rates in some studies, without impacting 
on overall survival (Kaufmann et al., 2005). Emerging evidence of the immunoregulatory 
effects of IFN signalling presented here and elsewhere (Teijaro et al., 2013; Wilson et al., 
2013) sheds light on these findings.    
 
The basis of resistance to ICB likely involves several interdependent, patient and tumour-
specific variables; i) The density of the targeted axis (receptor and ligand) and its relative 
contribution to suppression of T cell priming and effector function ii) the (neo)antigenic 
landscape of the tumour iii) the cellular and metabolic constitution of the tumour 
microenvironment (TME) iv) the differentiation and/or exhaustion status of tumour reactive 
T cells v) the intrinsic sensitivity of tumour cells to cytolytic effector mechanisms and vi) 
disease stage and/or duration and treatment history (Schietinger and Greenberg, 2014). The 
report by Benci et al connects several of these parameters to highlight a potentially clinically 
relevant component of tumour immune regulation. This phenomenon is perhaps best 
termed chronic resistance, defined as a STAT1-dependent, stable, epigenetically distinct 
tumour state, reached through prolonged IFN exposure and typified by ISG signatures and 
multiple TCIR ligand expression. 
 
The core feature of this report is that chronic IFN signalling portends expression of multiple 
TCIR ligands. However, lower efficacy of quadruple ICB relative to IFNA/G KO signifies the 
existence of novel inhibitory pathways, with corresponding candidate genes likely part of 
the wider chronic resistance program. In this regard, the contribution of type I IFNs in 
resistance (alluded to by the activity of single IFNAR KO) is tantalising and could be further 
resolved via deletion of ISGs in mouse models (e.g. MX1 or IFIT1), and/or corroborative in 
silico analysis to determine whether single nucleotide polymorphisms in this pathway 
associate with responses to ICB. The manuscript frames an emerging complex paradigm of 
IFNs in tumour immunology. Whilst intact tumour signalling via STAT1 permits enhanced 
antigen presentation (type I IFN) and susceptibility to cytotoxic potential or HLA-class II 
restricted recognition (IFNGR), antagonising chronic resistance ostensibly neutralizes 
regulation via recognised and novel immunomodulatory axes (Figure 1).  
 
As the authors suggest, scheduling of pharmacological intervention will require careful 
consideration. To this end, stratification of ICB non-responding or relapsed patients by 
neoantigen (NA) burden may best predict outcome using Jak inhibitors, with chronic 
resistance likely confined to patients with a larger number of NAs. This patient group is 
highlighted in the current report where progression is observed consistent with both high 
mutational burden and higher levels of MX1 and IFIT1. In keeping, several groups have 
observed STAT1 signatures in well infiltrated tumours, a marker which we found to be 
preferentially expressed in tumours of lung adenocarcinoma patients with high clonal NA 
burden (McGranahan et al., 2016). Determining whether the chronic resistance program is 
active within non-responding patients of this strata will add weight to the current report 
and support a rationale for Jak inhibition in similar demographics. In view of the potential 
unwanted effects, alternative strategies to bypass chronic resistance may be explored. In 
this respect, positive co-stimulation (e.g. via 41BB, OX40, ICOS) and/or gamma chain 
cytokines may be obvious candidates. In spite of these predictions there may be some utility 
in antagonizing presumably lower levels IFN signalling in the context of poorly immunogenic 
tumours, given the effectiveness in B16 melanoma.  
 
Advances in ICB research continue to elucidate key molecular pathways that govern 
resistance. The report by Benci et al reveals sustained IFN signalling as one such circuit, 
suppressing potentially curative anti-tumour T cell responses via established and novel 
immune regulatory networks. This mechanism of chronic resistance is amenable to existing 
pharmacologics, reasserting that collaborative efforts in T cell immunology, cancer cell 
biology, genetics and bioinformatics are providing drug targets of potential clinical 
relevance. However, whilst the approach is attractive, the complex pro- and anti-tumour 
effects of interferon signalling will require a cautious approach to future translational 
efforts. 
 
Figure Legend 
 
Figure1: Antagonising chronic resistance via IFN signalling blockade. Whilst chronic 
signalling via IFNs promotes the upregulation of PD-L1, ISGs and TCIRs on tumour cells 
fuelling resistance to immunotherapy, targeting this pathway requires a deeper 
understanding of the multiple activities of IFN in cancerous and normal cells. Targeting 
chronic IFN signalling can revert resistance via downregulation of PD-L1, ISGs and TCIR 
ligands on the tumour but it could also negatively impact antigen processing and 
presentation by tumour and antigen presenting cells, in a time dependent manner. 
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